Altimmune, Inc. (ALT) stock

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30

$1.65+0.03 (+2.17%)

Close on Nov 13, 2026Market cap $319.98MP/E –Yield –

Altimmune price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Altimmune's price to sales ratio was 202.0× on Jan 31, 2023, against 93.0× a year earlier. Over the last 5 years it ranged from 0.3× to 294.6×, with a median of 51.0×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2023	Jan 31, 2023	202.0×	−41.6
2022	Dec 30, 2022	243.7×	+138.1
2021	Dec 31, 2021	105.5×	+47.7
2020	Dec 31, 2020	57.9×	+54.1
2019	Dec 31, 2019	3.7×	+3.4
2018	Dec 31, 2018	0.3×	−3.1
2017	Dec 29, 2017	3.5×	–

Where these numbers come from

Parsed from the XBRL in Altimmune's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Sep 14, 2018
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALT.

Compare: ALT vs AVTX · ALT vs NTHI · ALT vs ADXN · ALT vs KZIA · ALT vs IXHL

Company	Revenue	Growth
ALT	$41.00K	+105.0%
AVTX	–	–
NTHI	–	–
ADXN	–	–
KZIA	–	–
IXHL	–	–

Company

Next earnings (est.): Mar 4, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 13
Held by institutions: 77.9%
Auditor: Ernst& Young LLP
SEC CIK: 1326190

Advertisement
300 × 250

See a number that looks wrong?

Altimmune price to sales ratio

Price to Sales Ratio at the end of each year

More Altimmune figures